Trials Sponsors Conditions Drugs Pricing

Conditions

Class IV Angina

Keywords

AnginaTransmyocardial revascularization

Outcome Measures

Primary Outcomes (1)

All Cause Mortality
Number of Participant Deaths
30 days

Secondary Outcomes (2)

Major Adverse Cardiovascular Events (MACE) Rate, Defined as the Incidence of Cardiac-related Death, Myocardial Infarction (Q-wave and Non Q-wave), Congestive Heart Failure, Cerebrovascular Accident, and Serious Arrhythmia
30 days
2 CCS Angina Class Reduction
30 days

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

All patients who meet the eligibility criteria and undergo TMR at the selected centers will be provided an opportunity to participate.

You may qualify if:

Class IV angina (according to Canadian Cardiovascular Society Angina Scale)

Sponsors & Collaborators

Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
Industrylead

Study Sites (24)

University of Arizona

Tuscon, Arizona, 85722, United States

California Cardiac Surgeons

Bakersfield, California, 93301, United States

The Vo Group

Fountain Valley, California, 92708, United States

Hurwitz & Roberts Med Corp

Glendale, California, 91204, United States

Advanced Cardiothoracic Surgery Medical Group

Los Angeles, California, 90017, United States

Soltero & Yasuda Associates Cardiothoracic & Vascular Medical Group

Northridge, California, 91325, United States

Cardiovascular & Thoracic Surgeons of Ventura County, APC

MeSH Terms

Conditions

Angina Pectoris

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesChest PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Results Point of Contact

Title: Scott Capps
Organization: CryoLife, Inc.

Study Officials

Scott Capps, MS
CryoLife, Inc.
STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee: No
Restriction Type: OTHER
Restrictive Agreement: Yes

Enrollment

203 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Target Duration: 30 Days
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 5, 2013

First Posted

April 9, 2013

Study Start

May 2013

Date type not reported

This date has not been verified as actual or estimated.

Cardiogenesis Transmyocardial Revascularization Registry

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (24)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (24)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations